News
Chief executive Mick Farrell says he’s confident the medical device company’s exports from Australia and Singapore will not ...
In a report released on April 10, Davinthra Thillainathan from Goldman Sachs maintained a Buy rating on Resmed Inc CHESS Depositary Interests ...
Last five quarters the last, 10 quarters where we said the actual market growth rate is mid-single digits on devices, high single digits on masks. And that's if ResMed just accepts market growth ...
Revenue Growth: ResMed displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 10.26%. This indicates a notable increase ...
Here’s what to look for. ResMed beat analysts’ revenue expectations by 1% last quarter, reporting revenues of $1.28 billion, up 10.3% year on year. It was a strong quarter for the company ...
A major Australian company has managed to secure a tariff exemption from the Trump Administration as the world waits to see ...
Revenue growth shifted from 10% in Q2 to 8% in Q3 ... risks related to global trade and tariffs but confirmed that ResMed's medical devices are exempt, mitigating financial impacts.
Morgan Stanley analyst David Bailey maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback